DOCSLIB.ORG

Impetigo & Ecthyma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Impetigo & Ecthyma Impetigo & Ecthyma (1 of 10) 1 Patient (usually a child) presents w/ skin lesions that are suggestive of impetigo or ecthyma 2 DIAGNOSIS No ALTERNATIVE Is impetigo or ecthyma DIAGNOSIS confi rmed? Yes 3 THERAPY Topical DECISION Oral antibiotic Does clinical condition warrant antibiotic use of a topical or oral antibiotic? A Pharmacological therapy A Pharmacological therapy (Topical) 1st-line: 1st-line: • Flucloxacillin • Fusidic Acid 2nd-line: 2nd-line: Any one of the following oral agents: • Bacitracin • Aminopenicillin/beta-lactamase inhibitor • Mupirocin • Cephalosporin (1st generation) • Retapamulin • Cephalosporin (2nd generation) B Patient education • Macrolide Alternative • Cephalosporin (3rd generation) B Patient education • FOLLOW-UP REVIEW DIAGNOSIS & THERAPY Yes Improvement after No 7-10 days of treatment? • ASSESS COMPLIANCE W/ THERAPY & HYGIENE MEASURES • DO CULTURE & SENSITIVITY NO FURTHER TREATMENT NECESSARY - Swab beneath lifted edge of • crusted lesion Longer treatment may be needed for ecthyma • - Nasal passage swab for TREAT BASED ON suspected carriers of CULTURE & Staphylococcus aureus SENSITIVITY RESULTS © • NASALMIMS MUPIROCIN FOR S aureus CARRIERS Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B168 © MIMS 2019 Impetigo & Ecthyma (2 of 10) 1 IMPETIGO & ECTHYMA Impetigo • A very contagious, superfi cial, bacterial skin infection that easily spreads among people in close contact • Most cases occur in children & resolve spontaneously w/o scarring in approximately 14 days • Complication: Risk of glomerulonephritis esp in children aged 2-6 yr Ecthyma • Deeply ulcerated form of impetigo that extends to the dermis - “Punched-out” ulcers w/ yellow crust & elevated violaceous margins • Most cases occur in children & elderly • May be a de novo infection or a superinfection 2 DIAGNOSIS • Diagnosis is usually based on clinical presentation Clinical Presentation Nonbullous Impetigo • Most common form of impetigo; also known as crusted impetigo or impetigo contagiosa • Most commonly occurs in children 2-5 yr of age • Initially presents w/ macules or papules that quickly become small vesicles - Vesicles quickly pustulate & rupture leaving an erosion or clusters of erosion - Purulent discharge dries & forms honey-colored crusts • Usually asymptomatic though local adenopathy is common; pruritus or pain may occur occasionally • Lesions are typically found on exposed areas of the skin on the face (esp around the nose & mouth) & extremities • Predisposing factors: Poor hygiene; warm climate; crowding; preceding skin breaks in the aff ected area from insect bites, wounds, viral infections (chicken pox, herpes simplex), scabies or burns; prior skin disease eg eczema, atopic dermatitis • Etiology: S aureus & group A beta-hemolytic streptococci (GABS) • Carrier state: 4% of adults may be asymptomatic carrier Bullous Impetigo • Newborns & younger children are commonly aff ected • Lesions (0.5-3 cm in diameter) typically develop on intact skin & begin as vesicles that turn into fl accid bullae that contain yellow serous fl uid IMPETIGO & ECTHYMA - Bullae rupture easily & a moist red-surfaced erosion appears surrounded by a thin rim of scale, which then forms a thin varnish-like light brown crust • Generally, there is no surrounding erythema but may have regional lymphadenopathy, pain or systemic symptoms • Lesions are often multiple, rapidly spread, & typically found on the face, buttocks, perineum & extremities, the trunk more frequently aff ected; in neonates, around the diaper area • Etiology: Always caused by coagulase-positive S aureus - A localized form of staphylococcal scalded skin syndrome Ecthyma • Typically occurs in children 6 mth-18 yr, in the elderly, immunocompromised (eg neutropenia, HIV), or patients w/ diabetes mellitus (DM) • Lesions initially appear as pustules & vesicles that become ulcerated - Ulceration is frequently covered by adherent crusts • Associated w/ pain & lymphadenopathy; heals w/ scarring • Lesions are usually found on the legs • Predisposing factors: Insect bites, scabies, pediculosis, poor hygiene & malnutrition, heat & high humidity • Etiology: Group A beta-hemolytic streptococci (Streptococcus pyogenes); S aureus is typically cultured from the lesions but is usually a secondary pathogen Lab Tests • Tests are not necessary in most cases because diagnosis is made on clinical grounds • Gram stain &/or culture may be used to confi rm the diagnosis when the clinical presentation is unclear or if the patient fails fi rst treatment - Gram stain smears of vesicles show Gram-positive cocci - Culture & sensitivity test reveals the causative agents & the appropriate therapy esp when resistant organisms are suspected© MIMS • Take blood cultures when patient appears ill & when infection is severe, recurrent, suspected to be an outbreak, or suspected to be caused by Methicillin-resistant S aureus (MRSA) B169 © MIMS 2019 Impetigo & Ecthyma (3 of 10) 2 DIAGNOSIS (CONT’D) Alternative Diagnosis • Infectious: Candidiasis, cellulitis, dermatophytosis, ecthyma, erysipelas , HSV, scabies, varicella • Non-infectious: Atopic eczema, burns & scalds, contact dermatitis, drug reaction, insect bites, Stevens-Johnson syndrome, toxic epidermal necrolysis • Rare: Bullous pemphigoid, pemphigus foliaceus 3 THERAPY DECISION • Duration of treatment is tailored according to clinical improvement - If unresponsive or deteriorating, it is reasonable to extend beyond 7 days while waiting for the C&S results Topical Antibiotic erapy • May be appropriate in localized nonbullous impetigo located away from the mouth (child may lick topical antibiotics if applied near the mouth) • Used to treat single lesions or small areas of involvement (localized impetigo) Oral Antibiotic erapy • Preferred treatment in patients w/ systemic symptoms, widespread nonbullous impetigo, lesions near the mouth, bullous impetigo, ecthyma patients in cases where there is evidence of deep involvement (eg cellulitis, furunculosis, etc), recurrent infection or in immunocompromised, those unable to tolerate topical antibiotics • Parenteral antibiotics may be needed for widespread ecthyma Others • Hygiene measures alone are not recommended even for localized lesions since untreated impetigo is highly communicable & may become generalized • Topical antiseptics (eg Hydrogen peroxide cream) are not recommended due to limited evidence regarding its eff ectiveness & its tendency to cause skin reactions Referral • A referral to a pediatrician or dermatologist may be considered when: - Diagnosis is unclear - Infection is extensive, severe, or unresponsive to maximal therapy in primary care setting - Recurrence is frequent IMPETIGO & ECTHYMA A PHARMACOLOGICAL THERAPY Topical Antibiotics • Must be applied after crust removal to enhance penetration - Soften crusts w/ a wet cloth compress - Removal of scabs during the process of healing is not recommended • Use should be limited to 2 wk due to risk of contact sensitization & antibiotic resistance development Fusidic Acid • 1st-line topical antibiotic • Eff ects: Has been proven to be as clinically eff ective as Mupirocin - Active against staphylococci (including Methicillin-resistant strains) & streptococci Other Topical Antibiotics Bacitracin • Used for many years as topical therapy for localized impetigo • Eff ects: Has been shown to be eff ective against S aureus and group A streptococci Mupirocin • Eff ects: Has been proven to be as eff ective as Fusidic acid & several oral antibiotics (eg Ampicillin, Dicloxacillin, Erythromycin & Cefalexin) for treatment of impetigo & produces fewer side eff ects than oral agents - Considered as 2nd-line of treatment after Fusidic acid, as it is active against staphylococci (including Methicillin-resistant strains) & streptococci • Carriers© of S aureus in their nares are treatedMIMS w/ mupirocin ointment applied nasally Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B170 © MIMS 2019 Impetigo & Ecthyma (4 of 10) A PHARMACOLOGICAL THERAPY (CONT’D) Retapamulin • New agent for treating impetigo w/ a short treatment duration of only 5 days • Considered as a 2nd line treatment because of its cost • Suitable alternative to Fusidic acid • Eff ects: Active against S aureus & streptococci - In vitro data show activity against Methicillin-resistant staphylococci Oral Antibiotics • Choice of agent will depend on suspected organism, local resistance patterns, cost & product availability Antistaphylococcal Penicillins • Dicloxacillin & Flucloxacillin - For infections caused by penicillinase-producing staphylococci - May be used to initiate therapy when staphylococcal infection is suspected - Very eff ective but less tolerated compared to Cefalexin - Does not cover MRSA • Amoxicillin + Clavulanate - Indicated for Impetigo and other skin and soft tissue infection caused by Staphylococcus aureus (MSSA) Cephalosporins (1st Generation) • Excellent activity against Methicillin-susceptible S aureus (MSSA) & S pyogenes & is generally well-tolerated • Do not cover MRSA Cephalosporins (2nd Generation) • Cefaclor, Cefprozil & Cefuroxime are among the choices Cephalosporins (3rd Generation) • Variable in their activity against Gram-positive organisms esp MSSA & no inherent advantage to the broader Gram-negative coverage - Broad spectrum of activity tends to exert an increased selective pressure for emergence of antibiotic resistance
Load more

Recommended publications
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • Bacterial Infections Diseases Picture Cause Basic Lesion
    page: 117 Chapter 6: alphabetical Bacterial infections diseases picture cause basic lesion search contents print last screen viewed back next Bacterial infections diseases Impetigo page: 118 6.1 Impetigo alphabetical Bullous impetigo Bullae with cloudy contents, often surrounded by an erythematous halo. These bullae rupture easily picture and are rapidly replaced by extensive crusty patches. Bullous impetigo is classically caused by Staphylococcus aureus. cause basic lesion Basic Lesions: Bullae; Crusts Causes: Infection search contents print last screen viewed back next Bacterial infections diseases Impetigo page: 119 alphabetical Non-bullous impetigo Erythematous patches covered by a yellowish crust. Lesions are most frequently around the mouth. picture Lesions around the nose are very characteristic and require prolonged treatment. ß-Haemolytic streptococcus is cause most frequently found in this type of impetigo. basic lesion Basic Lesions: Erythematous Macule; Crusts Causes: Infection search contents print last screen viewed back next Bacterial infections diseases Ecthyma page: 120 6.2 Ecthyma alphabetical Slow and gradually deepening ulceration surmounted by a thick crust. The usual site of ecthyma are the legs. After healing there is a permanent scar. The pathogen is picture often a streptococcus. Ecthyma is very common in tropical countries. cause basic lesion Basic Lesions: Crusts; Ulcers Causes: Infection search contents print last screen viewed back next Bacterial infections diseases Folliculitis page: 121 6.3 Folliculitis
    [Show full text]
  • Pharmaceutical Microbiology Table of Contents
    TM Pharmaceutical Microbiology Table of Contents Pharmaceutical Microbiology ������������������������������������������������������������������������������������������������������������������������ 1 Strains specified by official microbial assays ������������������������������������������������������������������������������������������������ 2 United States Pharmacopeia (USP) �������������������������������������������������������������������������������������������������������������������������������������������2 European Pharmacopeia (EP) Edition 8�1 ���������������������������������������������������������������������������������������������������������������������������������5 Japanese Pharmacopeia (JP) ������������������������������������������������������������������������������������������������������������������������������������������������������7 Strains listed by genus and species �������������������������������������������������������������������������������������������������������������10 ATCC provides research and development tools and reagents as well as related biological material management services, consistent with its mission: to acquire, authenticate, preserve, develop, and distribute standard reference THE ESSENTIALS microorganisms, cell lines, and related materials for research in the life sciences� OF LIFE SCIENCE For over 85 years, ATCC has been a leading authenticate and further develop products provider of high-quality biological materials and services essential to the needs of basic and standards to the life
    [Show full text]
  • Pseudomonas Skin Infection Clinical Features, Epidemiology, and Management
    Am J Clin Dermatol 2011; 12 (3): 157-169 THERAPY IN PRACTICE 1175-0561/11/0003-0157/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Pseudomonas Skin Infection Clinical Features, Epidemiology, and Management Douglas C. Wu,1 Wilson W. Chan,2 Andrei I. Metelitsa,1 Loretta Fiorillo1 and Andrew N. Lin1 1 Division of Dermatology, University of Alberta, Edmonton, Alberta, Canada 2 Department of Laboratory Medicine, Medical Microbiology, University of Alberta, Edmonton, Alberta, Canada Contents Abstract........................................................................................................... 158 1. Introduction . 158 1.1 Microbiology . 158 1.2 Pathogenesis . 158 1.3 Epidemiology: The Rise of Pseudomonas aeruginosa ............................................................. 158 2. Cutaneous Manifestations of P. aeruginosa Infection. 159 2.1 Primary P. aeruginosa Infections of the Skin . 159 2.1.1 Green Nail Syndrome. 159 2.1.2 Interdigital Infections . 159 2.1.3 Folliculitis . 159 2.1.4 Infections of the Ear . 160 2.2 P. aeruginosa Bacteremia . 160 2.2.1 Subcutaneous Nodules as a Sign of P. aeruginosa Bacteremia . 161 2.2.2 Ecthyma Gangrenosum . 161 2.2.3 Severe Skin and Soft Tissue Infection (SSTI): Gangrenous Cellulitis and Necrotizing Fasciitis. 161 2.2.4 Burn Wounds . 162 2.2.5 AIDS................................................................................................. 162 2.3 Other Cutaneous Manifestations . 162 3. Antimicrobial Therapy: General Principles . 163 3.1 The Development of Antibacterial Resistance . 163 3.2 Anti-Pseudomonal Agents . 163 3.3 Monotherapy versus Combination Therapy . 164 4. Antimicrobial Therapy: Specific Syndromes . 164 4.1 Primary P. aeruginosa Infections of the Skin . 164 4.1.1 Green Nail Syndrome. 164 4.1.2 Interdigital Infections . 165 4.1.3 Folliculitis .
    [Show full text]
  • Skin Disease and Disorders
    Sports Dermatology Robert Kiningham, MD, FACSM Department of Family Medicine University of Michigan Health System Disclosures/Conflicts of Interest ◼ None Goals and Objectives ◼ Review skin infections common in athletes ◼ Establish a logical treatment approach to skin infections ◼ Discuss ways to decrease the risk of athlete’s acquiring and spreading skin infections ◼ Discuss disqualification and return-to-play criteria for athletes with skin infections ◼ Recognize and treat non-infectious skin conditions in athletes Skin Infections in Athletes ◼ Bacterial ◼ Herpetic ◼ Fungal Skin Infections in Athletes ◼ Very common – most common cause of practice-loss time in wrestlers ◼ Athletes are susceptible because: – Prone to skin breakdown (abrasions, cuts) – Warm, moist environment – Close contacts Cases 1 -3 ◼ 21 year old male football player with 4 day h/o left axillary pain and tenderness. Two days ago he noticed a tender “bump” that is getting bigger and more tender. ◼ 16 year old football player with 3 day h/o mildly tender lesions on chin. Started as a single lesion, but now has “spread”. Over the past day the lesions have developed a dark yellowish crust. ◼ 19 year old wrestler with a 3 day h/o lesions on right side of face. Noticed “tingling” 4 days ago, small fluid filled lesions then appeared that have now started to crust over. Skin Infections Bacterial Skin Infections ◼ Cellulitis ◼ Erysipelas ◼ Impetigo ◼ Furunculosis ◼ Folliculitis ◼ Paronychea Cellulitis Cellulitis ◼ Diffuse infection of connective tissue with severe inflammation of dermal and subcutaneous layers of the skin – Triad of erythema, edema, and warmth in the absence of underlying foci ◼ S. aureus or S. pyogenes Erysipelas Erysipelas ◼ Superficial infection of the dermis ◼ Distinguished from cellulitis by the intracutaneous edema that produces palpable margins of the skin.
    [Show full text]
  • Necrotizing Fasciitis Report of 39 Pediatric Cases
    STUDY Necrotizing Fasciitis Report of 39 Pediatric Cases Antonio Fustes-Morales, MD; Pedro Gutierrez-Castrellon, MD; Carola Duran-Mckinster, MD; Luz Orozco-Covarrubias, MD; Lourdes Tamayo-Sanchez, MD; Ramon Ruiz-Maldonado, MD Background: Necrotizing fasciitis (NF) is a severe, Results: We examined 39 patients with NF (0.018% of life-threatening soft tissue infection. General features all hospitalized patients). Twenty-one patients (54%) were and risk factors for fatal outcome in children are not boys. Mean age was 4.4 years. Single lesions were seen in well known. 30 (77%) of patients, with 21(54%) in extremities. The most frequent preexisting condition was malnutrition in 14 pa- Objective: To characterize the features of NF in chil- tients (36%). The most frequent initiating factor was vari- dren and the risk factors for fatal outcome. cella in 13 patients (33%). Diagnosis of NF at admission was made in 11 patients (28%). Bacterial isolations in 24 Design: Retrospective, comparative, observational, and patients (62%) were polymicrobial in 17 (71%). Pseudo- longitudinal trial. monas aeruginosa was the most frequently isolated bacte- ria; gram-negative isolates, the most frequently associated Setting: Dermatology department of a tertiary care pe- bacteria. Complications were present in 33 patients (85%), diatric hospital. mortality in 7 (18%), and sequelae in 29 (91%) of 32 sur- viving patients. The significant risk factor related to a fatal Patients: All patients with clinical and/or histopatho- outcome was immunosuppression. logical diagnosis of NF seen from January 1, 1971, through December 31, 2000. Conclusions: Necrotizing fasciitis in children is fre- quently misdiagnosed, and several features differ from those Main Outcome Variables: Incidence, age, sex, num- of NF in adults.
    [Show full text]
  • Z:\My Documents\WPDOCS\IACUC
    ZOONOTIC DISEASES OF LABORATORY, AGRICULTURAL, AND WILDLIFE ANIMALS July, 2007 Michael S. Rand, DVM, DACLAM University Animal Care University of Arizona PO Box 245092 Tucson, AZ 85724-5092 (520) 626-6705 E-mail: [email protected] http://www.ahsc.arizona.edu/uac Table of Contents Introduction ............................................................................................................................................. 3 Amebiasis ............................................................................................................................................... 5 B Virus .................................................................................................................................................... 6 Balantidiasis ........................................................................................................................................ 6 Brucellosis ........................................................................................................................................ 6 Campylobacteriosis ................................................................................................................................ 7 Capnocytophagosis ............................................................................................................................ 8 Cat Scratch Disease ............................................................................................................................... 9 Chlamydiosis .....................................................................................................................................
    [Show full text]
  • Nature Nurtures the Design of New Semi-Synthetic Macrolide Antibiotics
    The Journal of Antibiotics (2017) 70, 527–533 OPEN Official journal of the Japan Antibiotics Research Association www.nature.com/ja REVIEW ARTICLE Nature nurtures the design of new semi-synthetic macrolide antibiotics Prabhavathi Fernandes, Evan Martens and David Pereira Erythromycin and its analogs are used to treat respiratory tract and other infections. The broad use of these antibiotics during the last 5 decades has led to resistance that can range from 20% to over 70% in certain parts of the world. Efforts to find macrolides that were active against macrolide-resistant strains led to the development of erythromycin analogs with alkyl-aryl side chains that mimicked the sugar side chain of 16-membered macrolides, such as tylosin. Further modifications were made to improve the potency of these molecules by removal of the cladinose sugar to obtain a smaller molecule, a modification that was learned from an older macrolide, pikromycin. A keto group was introduced after removal of the cladinose sugar to make the new ketolide subclass. Only one ketolide, telithromycin, received marketing authorization but because of severe adverse events, it is no longer widely used. Failure to identify the structure-relationship responsible for this clinical toxicity led to discontinuation of many ketolides that were in development. One that did complete clinical development, cethromycin, did not meet clinical efficacy criteria and therefore did not receive marketing approval. Work on developing new macrolides was re-initiated after showing that inhibition of nicotinic acetylcholine receptors by the imidazolyl-pyridine moiety on the side chain of telithromycin was likely responsible for the severe adverse events.
    [Show full text]
  • Skin and Soft Ssue Infec On
    Skin and so* +ssue infec+on N.Nuntachit MD. Non purulent SSTI • Impe+go, ecthyma • Celluli+s, Erysipelas • Erysipeloid • Necro+zing infec+on • Etc eg Glanders, bubonic plaque Purulent SSTI • Furuncle • Carbuncle • Abscess • Etc eg Tularemia SSTI severity • Purulent SSTI – Mild infec+on: I&D is indicated – Moderate: + systemic signs – Severe: failed I&D + ABT, systemic signs • Non purulent SSTI – Mild infec+on: no focus of purulence – Moderate: + systemic signs – Severe: failed oral ABTs, systemic signs, compromised, signs of deeper infecon Impe+go, Ecthyma • S.aureus or Beta hemoly+c streptococci • Difference – Depth – Scar • ABT should be ac+ve against both S. aureus and streptococci • Systemic therapy preferred – Pts with numerous lesions – Outbreaks Treatment An#bio#c Dosage Comment Dicloxacillin 250 mg po qid Cephalexin 250 mg po qid Erythromycin 250 mg po qid Some strains of Staphylococcus aureus and Streptococcus pyogenes may be resistant Clindamycin 300-400 mg po qid Amoxicillin-clavulanate 875/125 mg po bid Retapamulin ointment Apply lesions bid For paents with limited number of lesions Mupirocin ointment Apply lesions bid For paents with limited number of lesions Celluli+s, Erysipelas • Erysipelas • Cellulis – Upper dermis – Deeper dermis, – Delineated border subcutaneous fat – May be refer to celluli+s – No clear border of face • Areas of erythema, swelling, tenderness, and warmth, some+mes accompanied by lymphangi+s and inflammaon of the regional lymph nodes. The skin surface may resemble an orange peel (peau d’orange) Celluli+s,
    [Show full text]
  • WO 2016/120258 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2016/120258 A l 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/20 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP20 16/05 1545 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 26 January 2016 (26.01 .2016) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 264/MUM/2015 27 January 2015 (27.01 .2015) IN kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: JANSSEN PHARMACEUTICA NV TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).
    [Show full text]
  • US 2002/0071822 A1 Uhrich (43) Pub
    US 20020071822A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0071822 A1 Uhrich (43) Pub. Date: Jun. 13, 2002 (54) THERAPEUTIC POLYESTERS AND provisional application No. 60/261,337, filed on Jan. POLYAMIDES 12, 2001. (76) Inventor: Kathryn E. Uhrich, Hoboken, NJ (US) Publication Classification Correspondence Address: (51) Int. Cl." ..................... A61K 31/785; A61K 31/765; SCHWEGMAN, LUNDBERG, WOESSNER & C08G 63/685; CO8G 63/688 KLUTH, PA. (52) U.S. Cl. ....................... 424/78.37; 528/288; 528/293 P.O. BOX 2938 MINNEAPOLIS, MN 55402 (US) (57) ABSTRACT (21) Appl. No.: 09/917,194 Polymers (i.e. polyesters, polyamides, and polythioesters or (22) Filed: Jul. 27, 2001 a mixture thereof) which degrade hydrolytically into bio logically active compounds are provided. Methods of pro Related U.S. Application Data ducing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to (63) Non-provisional of provisional application No. deliver biologically active compounds to a host are also 60/220,707, filed on Jul. 27, 2000. Non-provisional of provided. US 2002/0071822 A1 Jun. 13, 2002 THERAPEUTIC POLYESTERS AND POLYAMDES 0012. The invention also provides processes and inter mediates disclosed herein that are useful for preparing a PRIORITY OF INVENTION polymer of the invention. 0001. This application claims priority from U.S. Provi DETAILED DESCRIPTION OF THE sional Application No. 60/220,707, filed Jul. 27, 2000 and INVENTION U.S. Provisional Application No. 60/261,337, filed Dec. 1, 2001, which are incorporated herein by reference. 0013 Definitions 0014. The following definitions are used, unless other BACKGROUND OF THE INVENTION wise described: halo is fluoro, chloro, bromo, or iodo.
    [Show full text]
  • Ecthyma Gangrenosum: a Rare Cutaneous Manifestation Caused by Stenotrophomonas Maltophilia in a Leukemic Patient
    Ann Dermatol Vol. 21, No. 4, 2009 CASE REPORT Ecthyma Gangrenosum: A Rare Cutaneous Manifestation Caused by Stenotrophomonas maltophilia in a Leukemic Patient Young Min Son, M.D., So Young Na, M.D., Hye Young Lee, M.D., Jin Ok Baek, M.D., Jong Rok Lee, M.D., Joo Young Roh, M.D. Department of Dermatology, Gachon University of Medicine and Science, Gil Medical Center, Incheon, Korea Ecthyma gangrenosum (EG) is a well-recognized cutaneous pressed and burn patients1,2. It usually occurs as a result of infection that most commonly affects immunocompromised bacteremia or, rarely, as a primary cutaneous lesion. The patients. It typically occurs on the extremities, or in gluteal lesions are present in the gluteal and perineal regions or and perineal regions. Although Pseudomonas aeruginosa is on the extremities, but they can occur anywhere on the the most well-known pathogen causing EG, other organisms body1,3,4. Most cases of ecthyma gangrenosum are asso- have been reported to cause EG. Herein we report a rare case ciated with Pseudomonas aeruginosa bacteremia5,6. But of ecthyma gangrenosum presenting as aggressive necrotic numerous other organisms have been reported to cause skin lesions in perioral and infraorbital areas in a 47-year-old EG. patient with acute myelocytic leukemia after allogeneic Stenotrophomonas maltophilia is an aerobic gram-neg- bone marrow transplantation. It was caused by Stenotropho- ative bacillus that is a frequent colonizer of fluids used in monas maltophilia, which is an aerobic, gram-negative hospital settings. The incidence of S. maltophilia infection pathogen that has been associated only rarely with cuta- has been increasing.
    [Show full text]